Intercept Pharmaceuticals, Inc. ICPT
At closeNov 7, 2023, 4:00 PM EST
52-week range unavailable
- Market cap
- 794.69M
- Revenue (ttm)
- 317.68M
- Profit margin
- -19.39%
- Shares out
- 41.83M
- Forward P/E
- 8.88
- Volume
- 3.91M
- Open
- 19.00
- Previous close
- 19.00
- Day's range
- 18.98 – 19.01
- Beta
- 0.88
- Analysts
- Hold
- Price target
- 19.00 (+0.0%)
- Earnings date
- Nov 6, 2023
2Y +1.33 (+7.53%)
Key statistics
- Enterprise value
- 695.84M
- PEG ratio
- 1.78
- Price / sales
- 2.50
- Price / book
- 11.06
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 14.40%
- Free cash flow
- -42.40M
- Total cash
- 322.71M
- Total debt
- 223.86M
- Return on equity
- -64.02%
- Short % of float
- 25.19%
- 50-day average
- 16.63
- 200-day average
- 14.55
Analyst view
Consensus: hold
- Strong buy3
- Buy7
- Hold8
- Sell2
- Strong sell0
Next earnings
Nov 6, 2023
Expected Nov 6, 2023. Consensus EPS estimate -0.09.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2023 | Sep 1, 2023 | -0.27 | — | — | — |
| Aug 2, 2023 | Jun 1, 2023 | -0.56 | — | — | — |
| Apr 27, 2023 | Mar 1, 2023 | -0.57 | — | — | — |
| Mar 2, 2023 | Dec 1, 2022 | -0.53 | — | — | — |
| Nov 1, 2022 | Sep 1, 2022 | 5.11 | — | — | — |
| Aug 3, 2022 | Jun 1, 2022 | -0.53 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 26, 2023 | Canaccord Genuity | down | Buy | Hold |
| Sep 26, 2023 | HC Wainwright & Co. | down | Buy | Neutral |
| Sep 26, 2023 | RBC Capital | main | Sector Perform | Sector Perform |
| Sep 26, 2023 | B. Riley Securities | down | Buy | Neutral |
| Aug 2, 2023 | Canaccord Genuity | main | Buy | Buy |
| Aug 2, 2023 | HC Wainwright & Co. | reit | — | Buy |
About Intercept Pharmaceuticals, Inc.
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey. As of November 8, 2023, Intercept Pharmaceuticals, Inc. operates as a subsidiary of Alfasigma S.p.A..
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- interceptpharma.com
News
Intercept Pharma withdraws liver disease drug from US market 
US FDA says Intercept's drug can cause liver injury in patients without scarring 
US FDA declines full approval for Intercept's liver disease drug 
Intercept Receives Complete Response Letter from FDA Addressing OCALIVA supplemental New Drug Application (sNDA) 
FDA advisers vote against confirmatory data for Intercept's liver disease drug 
FDA staff raises efficacy concerns over Intercept's liver disease drug 
Sophos Group (OTCMKTS:SPHHF) & Loomis AB (publ) (OTCMKTS:LOIMF) Financial Review 
Gilead (GILD) Announces Positive Interim Results on PBC Drug 
Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC 
Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.
Your note
Sign in to keep a note on ICPT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AKKARAJU SRINIVAS | Director | Stock Award(Grant) | May 23, 2023 | 686,686 |
| BERREY M MICHELLE | Officer | Stock Award(Grant) | Jan 26, 2023 | 83,877 |
| BRADBURY DANIEL M | Director | Stock Award(Grant) | May 23, 2023 | 39,471 |
| FUNDARO PAOLO | Director | Stock Award(Grant) | May 23, 2023 | 43,905 |
| GOTTESDIENER KEITH MICHAEL | Director | Stock Award(Grant) | May 23, 2023 | 32,830 |
| LUCA BENATTI | Director | Stock Award(Grant) | May 23, 2023 | 33,598 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 11.23% | 4,693,817 | 51.91M | Jun 29, 2023 |
| Blackrock Inc. | 10.52% | 4,396,970 | 48.63M | Jun 29, 2023 |
| State Street Corporation | 10.00% | 4,180,224 | 46.23M | Jun 29, 2023 |
| Deerfield Management Company, L.P. (Series C) | 4.97% | 2,077,893 | 22.98M | Jun 29, 2023 |
| UBS Group AG | 3.25% | 1,359,471 | 15.04M | Jun 29, 2023 |
| Caligan Partners, LP | 3.10% | 1,293,510 | 14.31M | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 8.31% | 3,473,737 | 37.62M | Aug 30, 2023 |
| Vanguard Strategic Equity Fund | 3.16% | 1,320,226 | 14.60M | Jun 29, 2023 |
| Vanguard Total Stock Market Index Fund | 2.69% | 1,123,441 | 12.43M | Jun 29, 2023 |
| Vanguard Explorer Fund, Inc. | 2.09% | 873,648 | 9.44M | Jul 30, 2023 |
| iShares Russell 2000 ETF | 1.35% | 563,326 | 6.10M | Aug 30, 2023 |
| Vanguard Extended Market Index Fund | 1.21% | 504,099 | 5.58M | Jun 29, 2023 |